OncoMatch/Clinical Trials/NCT06484816
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
Is NCT06484816 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TGRX-1942 for non small cell lung cancer.
Treatment: TGRX-1942 — A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Tumor Agnostic
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-tumor treatments
Received other anti-tumor treatments (i.e., chemotherapy, biologics, immunotherapy, targeted therapy, etc.) 28 days before first dose
Cannot have received: radiation therapy
radiation therapy 14 days before first dose
Cannot have received: investigational agent
Participated in other clinical trials and used other investigational agents 28 days before first dose
Cannot have received: immunosuppressant
Used immunosuppressant drugs within14 days before first dose
Cannot have received: vaccine
Received vaccine injection within 30 days of Cycle 1 Day 1
Lab requirements
Blood counts
Adequate hematologic function required
Kidney function
Adequate kidney function required
Liver function
Adequate hepatic function required
Adequate systemic and organ functions, including hematologic, hepatic and kidney functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify